Ryvu Therapeutics S.A. (RVU.WA)
PLN 36.5
(-3.95%)
PLN 36.5
(-3.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 120.36 Million PLN | -8.53% |
| 2022 | 131.58 Million PLN | 121.55% |
| 2021 | 59.39 Million PLN | -17.42% |
| 2020 | 71.91 Million PLN | 13.92% |
| 2019 | 63.13 Million PLN | 3.77% |
| 2018 | 60.83 Million PLN | 53.72% |
| 2017 | 39.57 Million PLN | 18.46% |
| 2016 | 33.4 Million PLN | 81.95% |
| 2015 | 18.36 Million PLN | 4.63% |
| 2014 | 17.54 Million PLN | 18.19% |
| 2013 | 14.84 Million PLN | 51.28% |
| 2012 | 9.81 Million PLN | 62.45% |
| 2011 | 6.04 Million PLN | -31.08% |
| 2010 | 8.76 Million PLN | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 188.54 Million PLN | 56.65% |
| 2024 Q2 | 201.24 Million PLN | 6.73% |
| 2023 Q2 | 121.97 Million PLN | 1.31% |
| 2023 Q1 | 120.39 Million PLN | -8.5% |
| 2023 FY | 120.36 Million PLN | -8.53% |
| 2023 Q4 | 120.36 Million PLN | -21.6% |
| 2023 Q3 | 153.52 Million PLN | 25.87% |
| 2022 Q3 | 55.73 Million PLN | -2.46% |
| 2022 Q1 | 50.36 Million PLN | -15.19% |
| 2022 Q2 | 57.13 Million PLN | 13.44% |
| 2022 FY | 131.58 Million PLN | 121.55% |
| 2022 Q4 | 131.58 Million PLN | 136.1% |
| 2021 Q2 | 60.32 Million PLN | -16.2% |
| 2021 Q1 | 71.99 Million PLN | 0.1% |
| 2021 Q3 | 55.56 Million PLN | -7.89% |
| 2021 Q4 | 59.39 Million PLN | 6.88% |
| 2021 FY | 59.39 Million PLN | -17.42% |
| 2020 Q4 | 71.91 Million PLN | 19.56% |
| 2020 Q1 | 61.99 Million PLN | -1.81% |
| 2020 FY | 71.91 Million PLN | 13.92% |
| 2020 Q2 | 55.86 Million PLN | -9.88% |
| 2020 Q3 | 60.15 Million PLN | 7.68% |
| 2019 Q2 | 99.96 Million PLN | 31.97% |
| 2019 Q4 | 63.13 Million PLN | -38.01% |
| 2019 Q1 | 75.74 Million PLN | 24.5% |
| 2019 FY | 63.13 Million PLN | 3.77% |
| 2019 Q3 | 101.85 Million PLN | 1.89% |
| 2018 Q4 | 60.83 Million PLN | 12.63% |
| 2018 FY | 60.83 Million PLN | 53.72% |
| 2018 Q2 | 50.25 Million PLN | 32.04% |
| 2018 Q1 | 38.06 Million PLN | -3.83% |
| 2018 Q3 | 54.01 Million PLN | 7.48% |
| 2017 Q3 | 36.91 Million PLN | 2.48% |
| 2017 Q4 | 39.57 Million PLN | 7.21% |
| 2017 FY | 39.57 Million PLN | 18.46% |
| 2017 Q2 | 36.02 Million PLN | 7.94% |
| 2017 Q1 | 33.37 Million PLN | -0.11% |
| 2016 Q1 | 17.22 Million PLN | -6.19% |
| 2016 FY | 33.4 Million PLN | 81.95% |
| 2016 Q4 | 33.4 Million PLN | 44.13% |
| 2016 Q3 | 23.18 Million PLN | 18.76% |
| 2016 Q2 | 19.51 Million PLN | 13.31% |
| 2015 Q4 | 18.36 Million PLN | 3.83% |
| 2015 Q1 | 14.98 Million PLN | -14.59% |
| 2015 Q2 | 20.2 Million PLN | 34.77% |
| 2015 Q3 | 17.68 Million PLN | -12.45% |
| 2015 FY | 18.36 Million PLN | 4.63% |
| 2014 Q4 | 17.54 Million PLN | -0.23% |
| 2014 FY | 17.54 Million PLN | 18.19% |
| 2014 Q1 | 15.72 Million PLN | 5.93% |
| 2014 Q2 | 17.26 Million PLN | 9.76% |
| 2014 Q3 | 17.58 Million PLN | 1.88% |
| 2013 Q3 | 14.29 Million PLN | 267.5% |
| 2013 Q4 | 14.84 Million PLN | 3.88% |
| 2013 FY | 14.84 Million PLN | 51.28% |
| 2013 Q2 | 3.88 Million PLN | 143.81% |
| 2013 Q1 | 1.59 Million PLN | -83.75% |
| 2012 Q4 | 9.81 Million PLN | 0.0% |
| 2012 FY | 9.81 Million PLN | 62.45% |
| 2011 FY | 6.04 Million PLN | -31.08% |
| 2010 FY | 8.76 Million PLN | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioceltix S.A. | 2.26 Million PLN | -5205.529% |
| BIOTON S.A. | 215.86 Million PLN | 44.243% |
| Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | -328.724% |
| Mabion S.A. | 90.47 Million PLN | -33.027% |
| Molecure S.A. | 11.34 Million PLN | -960.936% |
| NanoGroup S.A. | 1.49 Million PLN | -7977.327% |
| Pharmena S.A. | 1.9 Million PLN | -6214.795% |
| Poltreg S.A. | 39.58 Million PLN | -204.085% |
| Pure Biologics Spólka Akcyjna | 20.84 Million PLN | -477.405% |
| Synthaverse S.A. | 153.26 Million PLN | 21.469% |
| Urteste S.A. | 1.85 Million PLN | -6388.41% |